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An optimal METRIC for imaging in small bowel Crohn’s disease
Cross-sectional imaging has an essential role in the 
diagnostic workup and follow-up of Crohn’s disease 
given its ability to visualise the entire gastrointestinal 
tract and to assess both transmural and extramural 
disease manifestations, such as abscesses or fistulas. 
Management in Crohn’s disease has evolved beyond the 
control of clinical symptoms towards a treat-to-target 
strategy, which involves monitoring of therapeutic 
response through objective interval assessments 
to avoid long-term complications.1 In this regard, 
cross-sectional imaging is particularly helpful in the 
follow-up of patients with small bowel disease, in whom 
endoscopy is less feasible or is not possible.
The imaging modality of choice is largely centre-
specific and depends on local expertise, cost, and access. 
Nevertheless, with increasing awareness of radiation 
exposure, expert consensus statements recommend 
radiation-free techniques such as magnetic resonance 
enterography (MRE) and ultrasound as first-line imaging 
tests.2,3 Both MRE and ultrasound are widespread 
imaging techniques used for small bowel Crohn’s disease 
assessment and have a similar ability to detect Crohn’s 
disease presence and inflammatory activity. However, 
most studies comparing these techniques were done in 
a single centre, included small numbers of patients, and 
applied various study designs and reference standards.4 
METRIC is the first large-scale, multicentre, prospective 
study (n=284) directly comparing the diagnostic 
accuracy of MRE and ultrasound for the presence, extent, 
and activity of Crohn’s disease in newly diagnosed 
patients and patients with relapsing Crohn’s disease.5 
For this purpose, all patients had MRE and ultrasound, 
and a diagnostic test comparison was performed 
against a consensus panel reference standard. This 
panel incorporated all relevant information obtained 
during a 6-month follow-up period (including clinical, 
biochemical, and endoscopic data) to judge whether MRE 
and ultrasound had adequately diagnosed small bowel 
disease extent (primary outcome) and were accurate 
in terms of disease location and activity (secondary 
outcomes). MRE had a higher accuracy than ultrasound 
for the extent and activity of small bowel Crohn’s disease. 
However, this result was not the case for colonic disease, 
in which the overall diagnostic accuracy for MRE and 
ultrasound was lower than for small bowel disease.
A major advance in the assessment of Crohn’s disease 
has been the validation of MRE-based disease activity 
scores, such as the Magnetic Resonance Index of 
Actvity score and the (extended) London index.6,7 The 
METRIC study includes established criteria, such as wall 
thickness, mural oedema, and bowel wall enhancement, 
to assess disease activity, but no validated MRE scoring 
system was used. Indeed, because most scoring systems 
are time consuming and require trained practitioners, 
routine radiological practice generally uses visual 
assessment only. However, a more objective assessment 
of disease activity and treatment response should be 
pursued and is indispensable in a clinical trial setting. 
An emerging technology, radiomics, enables automated 
quantification of many imaging features from medical 
images, such as intensity-based and textural properties.8 
Radiomics has proven to be useful in clinical oncology 
but has not yet been thoroughly investigated for 
Crohn’s disease.8
The METRIC study investigators5 correctly state that 
disease location and extent are important to determine 
the therapeutic strategy (eg, the option of an ileocaecal 
resection for limited terminal ileal disease vs medical 
therapy for ileocolonic or extended small bowel disease). 
However, correct differentiation between inflammatory 
and fibrotic strictures to initiate stage-adjusted therapy 
is even more important. Indeed, a predominantly 
inflammatory stricture is expected to respond to 
medical treatment, whereas a fibrotic stricture usually 
requires surgery. Unfortunately, current imaging tech-
niques, including standard MRE, do not have validated 
diagnostic accuracy for distinction between active 
inflammation and fibrosis in Crohn’s disease.2,9,10 New 
imaging tools, such as magnetisation transfer MR, 
shear wave velocity ultrasound, and photoacoustic 
imaging, seem capable of measuring intestinal fibrosis 
and are being further explored.3,4 Identification of high-
risk patients who are expected to require surgery not 
only has substantial clinical implications but will also 
facilitate clinical trial design for antifibrotic therapy, 
with several promising candidate therapies in the 
development pipeline.9
In summary, although the METRIC study obviously 
has some limitations (eg, the absence of a standardised 
imaging protocol, image interpretation only by expert 
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radiologists, and potential bias of the consensus panel), 
this pragmatic trial provides compelling data to support 
MRE as the first-line imaging tool for detecting disease 
presence and activity in patients with small bowel 
Crohn’s disease. Future research should particularly 
focus on the ability of imaging techniques to adequately 
monitor therapy and to predict responsiveness to anti-
inflammatory therapy in these patients. 
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